Clinical research
Junshi Biosciences announced that the Phase III clinical trial it is conducting alongside Coherus BioSciences on a potential non-small cell lung cancer drug shows positive preliminary results.
XVR011 is being observed in a randomized, double-blind, single-center, and placebo-controlled study to evaluate its pharmacokinetic activity and safety profile.
Two months after Athira placed its CEO Leen Kawas, on temporary leave, the company has appointed new execs to its team. It is also rigorously advancing its Alzheimer’s program.
Moderna is expected to launch a human clinical trial as early as this week for an mRNA-based vaccine against HIV and indicated that it is looking for 56 people ages 18 to 50 who are HIV-negative.
As the COVID-19 pandemic continues with surges in the U.S. in unvaccinated people, biopharma companies are still working on new vaccines and therapies against the disease.
An interim analysis of a Phase III study shows that a combination of Innovent’s sintilimab with chemotherapy significantly improves overall survival compared with placebo in the first-line management of patients with advanced gastric cancer.
By administering a vaccine directly into the nasal cavity, the mucus membranes of the nose and throat would provide better protection than the intramuscular alone.
Patient enrollment in the Phase I study will resume, the company announced this morning.
Eli Lilly has announced the success of its clinical trial on lebrikizumab as a treatment for people diagnosed with moderate to severe atopic dermatitis.
There was plenty of clinical trial updates last week. Here’s a look.
PRESS RELEASES